Media stories about BioDelivery Sciences International (NASDAQ:BDSI) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioDelivery Sciences International earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 46.1294806105961 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Several equities research analysts have recently issued reports on the stock. ValuEngine lowered shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of BioDelivery Sciences International in a report on Friday, June 23rd. Piper Jaffray Companies set a $4.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a report on Wednesday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.50 price objective on shares of BioDelivery Sciences International in a report on Monday, August 14th. Finally, Janney Montgomery Scott increased their price objective on shares of BioDelivery Sciences International from $3.00 to $4.00 and gave the company a “fair value” rating in a report on Monday, July 24th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $4.21.

BioDelivery Sciences International (NASDAQ:BDSI) remained flat at $2.95 on Friday. 199,047 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $3.08 and a 200 day moving average price of $2.47. BioDelivery Sciences International has a one year low of $1.50 and a one year high of $3.60. The stock has a market cap of $163.65 million, a price-to-earnings ratio of 105.36 and a beta of 1.04.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.04). The business had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.45 million. BioDelivery Sciences International had a return on equity of 14.64% and a net margin of 3.34%. The firm’s revenue for the quarter was up 74.0% on a year-over-year basis. During the same period last year, the company posted ($0.31) earnings per share. On average, equities research analysts predict that BioDelivery Sciences International will post $0.12 earnings per share for the current year.

In related news, insider Mark A. Sirgo sold 201,373 shares of the stock in a transaction dated Thursday, September 21st. The shares were sold at an average price of $2.84, for a total value of $571,899.32. Following the sale, the insider now owns 1,509,262 shares of the company’s stock, valued at approximately $4,286,304.08. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Mark A. Sirgo sold 65,405 shares of the stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $2.75, for a total transaction of $179,863.75. Following the completion of the sale, the chief executive officer now directly owns 1,509,262 shares in the company, valued at approximately $4,150,470.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 402,127 shares of company stock worth $1,142,798. Corporate insiders own 9.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “BioDelivery Sciences International (BDSI) Receives Daily News Sentiment Rating of 0.15” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.watchlistnews.com/biodelivery-sciences-international-bdsi-receives-daily-news-sentiment-rating-of-0-15/1601097.html.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.